Ragifilimab is under clinical development by Incyte and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Ragifilimab’s likelihood of approval (LoA) and phase transition for Cervical Cancer took place on 17 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 17 Feb 2022 increased Ragifilimab’s LoA and PTSR for Esophageal Cancer, increased LoA and PTSR for Gastric Cancer, and increased LoA and PTSR for Head And Neck Cancer Squamous Cell Carcinoma.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ragifilimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
INCAGN-1876 is under development for advanced or metastatic solid tumors such as recurrent glioblastoma multiforme and relapsed melanoma, metastatic cervical cancer, gastric cancer including stomach, esophageal, and adenocarcinoma of gastroesophageal Junction (GEJ), squamous cell carcinoma of the head and neck (SCCHN), oral cavity (mouth) cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer. It is administered intravenously as a solution concentrate. It is a monoclonal antibody targeting GITR (glucocorticoid induced tumor necrosis factor receptor). The drug candidate is based on the retrocyte display technology. It was also under development for hematological malignancies, metaststic melanoma,metastatic adenocarcinoma of endometrium, non-small cell lung cancer, urothelial carcinoma and renal cell carcinoma.
Incyte is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.
Quick View Ragifilimab LOA Data
|Highest Development Stage|